Conjugates of anti-SLC34A2 antibodies and their uses
By designing anti-SLC34A2 antibody drug conjugates with specific CDR sequences, the safety and efficacy deficiencies of existing ADCs in targeting the SLC34A2 protein were addressed, achieving highly efficient killing of cancer cells and inhibition of tumor growth.
Patent Information
- Application Number
- CN202480088100.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-12-21
- Filing Date
- 2024-12-20
- Publication Date
- 2026-11-17
AI Technical Summary
Existing antibody-drug conjugates (ADCs) have shortcomings in safety and efficacy when targeting the SLC34A2 protein, especially in cancer treatment, and there is a need to develop more effective and safer ADCs.
An anti-SLC34A2 antibody-drug conjugate was designed, containing specific CDR sequences of heavy and light chain variable regions, which are conjugated to the drug moiety via a linker. A cytotoxic agent was selected as the drug moiety to target the SLC34A2 protein and inhibit the growth of cancer cells.
In vivo experiments showed that it has strong killing activity against NaPi2b-expressing cell lines and effectively inhibits tumor growth, providing a more efficient tumor treatment option.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Cross-reference to related applications
[0001] This application claims the benefit of International Application No. PCT / CN2023 / 140633, filed on December 21, 2023, the contents of which are incorporated herein by reference in their entirety.
[0002] Reference for electronic sequence listing The contents of the electronic serial number (371464.xml; size: 16,805 bytes; creation date: December 19, 2024) are incorporated herein by reference in full. Background Technology
[0003] Compared to neighboring normal cells, cell membrane transport proteins (such as those belonging to the glucose transporter GLUT, ATP-binding cassette transporters ABC, and solute carrier transporters SLC) are frequently upregulated in cancer cells. High levels of these transporters have been found in various solid tumors and are associated with low survival. One potential molecular tumor marker could be the sodium-dependent phosphate transporter NaPi2b, encoded by the SLC34A2 (solute carrier 34 A2) gene.
[0004] SLC34A2 encodes a type II Na / Pi cotransporter (NaPi2b), a multi-transmembrane sodium-dependent phosphate transporter responsible for the transcellular uptake of inorganic phosphate. NaPi2b is highly abundant in the brush border membrane of the small intestine, where it participates in the transcellular flow of inorganic phosphate across the apical membrane of epithelial cells. The expression of the sodium-dependent phosphate transporter NaPi2b has been reported to be altered in ovarian, lung, gastric, thyroid, and other cancers. Currently, NaPi2b is a target of the therapeutic antibodies XMT-1536 and RG-7599, both of which are in clinical trials for the treatment of ovarian and lung cancer.
[0005] Antibody-drug conjugates (ADCs) are among the rapidly developing anticancer drugs. This approach involves a mAb conjugated to a cytotoxic payload via a chemical linker. This mAb targets a target antigen expressed on the surface of cancer cells, thereby reducing systemic exposure and thus decreasing toxicity. ADCs are complex molecules requiring careful attention to their various components. Selecting appropriate targets, mAbs, cytotoxic payloads, and the way the antibody is conjugated to the payload are key determinants of the safety and efficacy of ADCs.
[0006] There is a need to develop more effective and safer clinical candidates that target the SLC34A2 protein with potent cytotoxic payloads. Summary of the Invention
[0007] The antibody-drug conjugate against SLC34A2 presented in this paper was found to have strong cytotoxic activity against cell lines expressing human NaPi2b. The ADC also demonstrated effective in vivo efficacy in inhibiting tumor growth at different concentrations in various tumor models.
[0008] Therefore, one embodiment of this disclosure provides an antibody-drug conjugate comprising an antibody or antigen-binding fragment thereof partially conjugated to a drug, wherein the antibody or antigen-binding fragment thereof has binding specificity to human lysosome carrier 34A2 (SLC34A2) protein and comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises heavy chain complementarity-determining regions VH CDR1, VH CDR2, and VH CDR3, and the light chain variable region comprises light chain complementarity-determining regions VL CDR1, VL CDR2, and VL CDR3, wherein VH CDR1 comprises the amino acid sequence of SEQ ID NO: 3, VH CDR2 comprises the amino acid sequence of SEQ ID NO: 4 or 9, VH CDR3 comprises the amino acid sequence of SEQ ID NO: 5, VL CDR1 comprises the amino acid sequence of SEQ ID NO: 6, VL CDR2 comprises the amino acid sequence of SEQ ID NO: 7, and VL CDR3 comprises the amino acid sequence of SEQ ID NO: 8.
[0009] In some embodiments, the VH CDR1 contains the amino acid sequence of SEQ ID NO: 3, the VH CDR2 contains the amino acid sequence of SEQ ID NO: 4, the VH CDR3 contains the amino acid sequence of SEQ ID NO: 5, the VLCDR1 contains the amino acid sequence of SEQ ID NO: 6, the VL CDR2 contains the amino acid sequence of SEQ ID NO: 7, and the VL CDR3 contains the amino acid sequence of SEQ ID NO: 8.
[0010] In some embodiments, the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1 and 10 to 13, and the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 2 and 14 to 17. In some embodiments, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 11, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 14.
[0011] In some embodiments, the antibody or its antigen-binding fragment further comprises a heavy chain constant region, a light chain constant region, an Fc region, or a combination thereof. In some embodiments, the antibody or its antigen-binding fragment is an isotype of IgG1, IgG2, IgG3, or IgG4. In some embodiments, the antibody or its antigen-binding fragment is an isotype of human IgG1.
[0012] In some embodiments, the pharmaceutical portion is a cytotoxic agent or cell inhibitor, an immunosuppressant, a radioactive isotope, or a toxin. In some embodiments, the pharmaceutical portion is selected from the group consisting of: auristatin, maytansine alkaloids, macrocyclic ketone analogs, topoisomerase inhibitors, benzodiazepines, tubulolysin, pyroxine, camptothecin, chalcogenine, eczemaconazole, irinotecan (SN38), doxorubicin, anthracycline, pyrrolobenzodiazepines (PBD), TLR agonists, STING agonists, Pseudomonas aeruginosa exotoxin PE38, diphtheria toxin, Staphylococcus aureus enterotoxin A / E-120, antimicrobial antibiotics, Shiga toxin, ricin, and urease.
[0013] In some embodiments, the pharmaceutical portion is a cytotoxic agent selected from the group consisting of: monomethylaurestatin E (MMAE), monomethylaurestatin F (MMAF), maytansine, metansine (DM1), lavtansine (DM4), tubulolysin A, DXd, 7-ethyl-10-hydroxycamptothecin (SN-38), DGN462, amberstatin 269, atrazomycin, SG3199 / SCX, IRDye®700DX, TLR7 / 8 agonists, diABZI STING agonist-2, or any derivative thereof. In some embodiments, the pharmaceutical portion includes MMAE, MMAF, or DXd.
[0014] In some embodiments, the pharmaceutical portion comprises a compound selected from the group consisting of:
[0015] (LM-D01)
[0016] (LM-D02) and
[0017] (LM-D03).
[0018] In some embodiments, the antibody or its antigen-binding fragment is conjugated to the drug via a connector. In some embodiments, the connector is a cleavable connector or a non-cleavable connector. In some embodiments, the connector is a cleavable connector.
[0019] In some embodiments, the connector includes succinimide-4-(N-maleimidemethyl)cyclohexane-1-carboxylic acid ester (SMCC), sulfonyl-SMCC, p-carboxycyclohexylmethylmaleimide, maleimide-hexanoyl (MC)-valine-citrulline (VC)-p-aminobenzyloxycarbamoyl (PABC), CL2A, maleimide-hexanoyl (MC), MC-glycine-glycine-phenylalanine-glycine (GGFG), MC-PEG8-GGFG, MC-PEG8-GGFG-PAB, or maleimide propionyl (MP)-PEG8-valine-alanine (VA)-PABC.
[0020] In some implementations, the antibody-drug conjugate includes ozogamicin, vedotin, mafodotin, emtansine, deruxtecan, govitecan, or tesirine.
[0021] In some embodiments, the drug-antibody ratio (DAR) is between 1 and 20. In some embodiments, the drug-antibody ratio (DAR) is between 4 and 8.
[0022] In some embodiments, compositions comprising an ADC and a pharmaceutically acceptable carrier are also provided.
[0023] Methods and uses for treating diseases and conditions are also provided. In one embodiment, a method for treating cancer in a patient in need is provided, the method comprising administering the ADC of this disclosure to the patient. Attached Figure Description
[0024] Figure 1 The role of ADC in inhibiting the proliferation of cells expressing NaPi2b is shown.
[0025] Figure 2 The effect of ADC in reducing tumors in the OVCAR-3 model is shown.
[0026] Figure 3 The effect of ADC in reducing tumors in the NCI-H1975 / H_NaPi2b model is shown. Detailed Implementation
[0027] definition It should be noted that the term "a" or "an" entity refers to one or more entities within that entity; for example, "antibody" should be understood to represent one or more antibodies. Therefore, the terms "a" (or "an"), "one or more," and "at least one" are used interchangeably in this document.
[0028] As used herein, the term "polypeptide" is intended to include both the singular and plural forms of "polypeptide" and refers to a molecule composed of monomers (amino acids) linearly linked by amide bonds (also known as peptide bonds). The term "polypeptide" refers to any one or more chains of two or more amino acids and does not refer to a specific length of the product. Therefore, peptide, dipeptide, tripeptide, oligopeptide, "protein," "amino acid chain," or any other term used to refer to one or more chains of two or more amino acids is included within the definition of "polypeptide," and the term "polypeptide" may be used in place of or interchangeably with any of these terms. The term "polypeptide" also refers to products of post-expression modifications, including but not limited to glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting / blocking groups, lysosomal cleavage, or modification by non-naturally occurring amino acids. Polypeptides may be derived from natural biological sources or produced through recombinant technologies, but are not necessarily translated from a specified nucleic acid sequence. They can be produced in any manner, including through chemical synthesis.
[0029] "Homology," "identity," or "similarity" refers to the sequence similarity between two peptides or two nucleic acid molecules. Homology can be determined by comparing positions in each sequence that can be compared for comparative purposes. When a position in the compared sequences is occupied by the same base or amino acid, the molecules are homologous at that position. The degree of homology between sequences varies with the number of matching or homologous positions shared by the sequences. An "irrelevant" or "non-homologous" sequence has less than 40% identity with one of the sequences in this disclosure, but preferably less than 25% identity.
[0030] "Sequence identity" of a polynucleotide or polynucleotide region (or polypeptide or polypeptide region) with another sequence at a certain percentage (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%) means that when the two sequences are compared, that percentage of bases (or amino acids) are the same.
[0031] The term "equivalent nucleic acid or polynucleotide" refers to a nucleic acid having a nucleotide sequence that shares a degree of homology or sequence identity with the nucleotide sequence of that nucleic acid or its complement. Homologs of double-stranded nucleic acids are intended to include nucleic acids having a nucleotide sequence that shares a degree of homology with it or its complement. In one respect, a homolog of a nucleic acid is capable of hybridizing with a nucleic acid or its complement. Similarly, "equivalent polypeptide" refers to a polypeptide that shares a degree of homology or sequence identity with the amino acid sequence of a reference polypeptide. In some respects, the sequence identity is at least about 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%. In some respects, the equivalent polypeptide or polynucleotide has one, two, three, four, or five additions, deletions, substitutions, and combinations thereof compared to the reference polypeptide or polynucleotide. In some respects, the equivalent sequence retains the activity (e.g., epitope binding) or structure (e.g., salt bridge) of the reference sequence.
[0032] As used herein, "antibody" or "antigen-binding polypeptide" refers to a polypeptide or polypeptide complex that specifically recognizes and binds to an antigen. An antibody can be a complete antibody or any antigen-binding fragment or single chain thereof. Therefore, the term "antibody" includes any protein or peptide containing a molecule that comprises at least a portion of an immunoglobulin molecule having biological activity of binding to an antigen. Such examples include, but are not limited to, the complementarity-determining region (CDR), variable region, constant region, frame (FR) region, or any portion thereof of the heavy or light chain or its ligand-binding moiety, or at least a portion of the binding protein.
[0033] As used herein, the term "antibody fragment" or "antigen-binding fragment" refers to a portion of an antibody (e.g., F(ab')2, F(ab)2, Fab', Fab, Fv, scFv, etc.). Regardless of its structure, an antibody fragment binds to the same antigen recognized by the intact antibody. The term "antibody fragment" includes aptamers, mirror isoforms, and biantibodies. The term "antibody fragment" also includes any synthetic or genetically engineered protein that functions like an antibody by binding to a specific antigen to form a complex.
[0034] "Single-chain variable fragment" or "scFv" refers to the variable region (V) of the heavy chain of immunoglobulins. H ) and the variable region (V) of the light chain L These are fusion proteins. In some respects, these regions are linked to short linker peptides consisting of 10 to approximately 25 amino acids. The linker can be enriched with glycine for flexibility and with serine or threonine for solubility, and can carry V... H N-terminus and V LThe C-terminus is linked, and vice versa. Despite the removal of the constant region and the introduction of a linker, the protein retains the specificity of the original immunoglobulin. scFv molecules are known in the art and are described, for example, in U.S. Patent 5,892,019.
[0035] The term antibody encompasses major classes of polypeptides that can be distinguished biochemically. Those skilled in the art will understand that heavy chains are classified as γ, μ, α, δ, or ε, and some subclasses therein (e.g., γ1-γ4). The nature of this chain determines the "class" of the antibody, which is IgG, IgM, IgA, IgG, or IgE, respectively. Immunoglobulin subclasses (isotypes) (e.g., IgG1, IgG2, IgG3, IgG4, IgG5, etc.) have been well characterized and are known to confer functional specialization. Modifications to each of these classes and isotypes according to this disclosure are readily identifiable to those skilled in the art and therefore fall within the scope of this disclosure. All immunoglobulin classes clearly fall within the scope of this disclosure, and the following discussion will generally pertain to the IgG class of immunoglobulin molecules. For IgG, a standard immunoglobulin molecule comprises two identical light chain polypeptides with a molecular weight of approximately 23,000 Daltons, and two identical heavy chain polypeptides with a molecular weight of 53,000 to 70,000 Daltons. These four chains are usually connected by disulfide bonds to form a "Y" configuration, in which the light chain starts from the opening of the "Y" and runs through the variable region to surround the heavy chain.
[0036] The antibodies, antigen-binding peptides, variants, or derivatives thereof disclosed herein include, but are not limited to, polyclonal antibodies, monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, primate-derived antibodies, or chimeric antibodies, single-chain antibodies, epitope-binding fragments (e.g., Fab, Fab', and F(ab')2, Fd, Fv, single-chain Fv (scFv)), single-chain antibodies, disulfide-linked Fv (sdFv), fragments containing VK or VH domains, fragments generated from Fab expression libraries, and anti-idiotype (anti-Id) antibodies (including, for example, anti-Id antibodies against the LIGHT antibodies disclosed herein). The immunoglobulin or antibody molecules disclosed herein can be any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass of immunoglobulin molecules.
[0037] Light chains are classified as or Each heavy chain class can bind to either a κ or λ light chain. Typically, when immunoglobulins are produced by hybridomas, B cells, or genetically engineered host cells, the light and heavy chains are covalently linked, and the "tail" portions of the two heavy chains are linked together via covalent disulfide bonds or non-covalent bonds. In the heavy chain, the amino acid sequence extends from the N-terminus of the Y-configuration to the C-terminus at the bottom of each chain.
[0038] Both light and heavy chains are divided into structural homologous regions and functional homologous regions. The terms "constant" and "variable" are used according to function. In this regard, it should be understood that the variable domains (VK) of the light chain and the variable domains (VH) of the heavy chain determine antigen recognition and specificity. Conversely, the constant domains (CK) of the light chain and the constant domains (CH1, CH2, or CH3) of the heavy chain confer important biological properties (e.g., secretion, transplacental migration, Fc receptor binding, complement binding, etc.). By convention, the numbering of constant domains increases with their distance from the antibody's antigen-binding site or N-terminus. The N-terminal portion is the variable region, and the C-terminal portion is the constant region; the CH3 and CK domains actually contain the carboxyl terms of the heavy and light chains, respectively.
[0039] As shown above, the variable region allows antibodies to selectively recognize and specifically bind to epitopes on antigens. That is, subsets of the antibody's VK and VH domains, or complementarity-determining regions (CDRs), combine to form a variable region defining a three-dimensional antigen-binding site. This quaternary antibody structure forms antigen-binding sites at the ends of each arm of the Y. More specifically, this antigen-binding site is defined by three CDRs (i.e., CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3) on each of the VH and VK chains. In some cases (e.g., for certain immunoglobulin molecules derived from camel species or engineered based on camel immunoglobulins), the complete immunoglobulin molecule may consist only of the heavy chain, without the light chain. See, for example, Hamers-Casterman et al. Nature 363:446-448 (1993).
[0040] In naturally occurring antibodies, the six complementarity-determining regions (CDRs) present in each antigen-binding domain are short, discontinuous amino acid sequences. These sequences are specifically localized to form the antigen-binding domain when the antibody assumes its three-dimensional conformation in an aqueous environment. The remaining amino acids in the antigen-binding domain (called the "framework" region) exhibit less intermolecular variability. The framework region primarily utilizes... - Folded conformation, while CDRs form rings, these rings connect - Folded structure, and in some cases formed - Part of the folded structure. Therefore, the framework region acts as a backbone that positions the CDR in the correct orientation via interchain non-covalent interactions. The antigen-binding domain formed by the positioned CDR defines a surface complementary to an epitope on an immunoreactive antigen. This complementary surface facilitates non-covalent binding of the antibody to its homologous epitope. For any given heavy or light chain variable region, those skilled in the art can readily identify the amino acids containing the CDR and framework region, respectively, as they have been precisely defined (see "Sequences of Proteins of Immunological Interest," Kabat, E et al., US Department of Health and Human Services, (1983); and Chothia and Lesk, J. MoI. Biol ., 196:901-917 (1987)).
[0041] Where two or more definitions exist for terms used and / or accepted in this field, the definitions of terms as used herein are intended to include all such meanings unless explicitly stated otherwise. A specific example is the use of the term “complementarity-determining region” (“CDR”) to describe discontinuous antigen-binding sites found within the variable regions of both heavy-chain and light-chain polypeptides. This specific region has been described in Kabat et al., US Dept. of Health and Human Services, “Sequences of Proteins of Immunological Interest” (1983) and Chothia et al. J. MoI. Biol References , 196:901-917 (1987), the full text of which are incorporated herein by reference. The CDR definition according to Kabat and Chothia includes overlap or subsets of amino acid residues when compared with each other. However, the application of any definition of a CDR relating to antibodies or variants thereof is intended to fall within the scope of the terminology as defined and used herein. The appropriate amino acid residues containing a CDR as defined in each of the foregoing references are listed in the table below for comparison. The exact number of residues containing a particular CDR will vary depending on the sequence and size of the CDR. Those skilled in the art can routinely determine which residues contain a particular CDR based on the amino acid sequence of the variable region of an antibody.
[0042]
[0043] Kabat et al. also defined a numbering system applicable to the variable domain sequences of any antibody. Those skilled in the art can explicitly assign this “Kabat numbering” system to any variable domain sequence without relying on any experimental data outside of the sequence itself. As used herein, “Kabat numbering” refers to the numbering system proposed by Kabat et al., US Dept. of Health and Human Services, “Sequence of Proteins of Immunological Interest” (1983).
[0044] In addition to the table above, the Kabat numbering system describes the CDR regions as follows: CDR-H1 begins at approximately the 31st amino acid (i.e., approximately 9 residues after the first cysteine residue), consists of approximately 5 to 7 amino acids, and ends at the next tryptophan residue. CDR-H2 begins at the 15th residue after the end of CDR-H1, consists of approximately 16 to 19 amino acids, and ends at the next arginine or lysine residue. CDR-H3 begins at approximately the 33rd amino acid residue after the end of CDR-H2; consists of 3 to 25 amino acids; and ends at the sequence WGXG, where X is any amino acid. CDR-L1 begins at approximately the 24th residue (i.e., after the cysteine residue); consists of approximately 10 to 17 residues; and ends at the next tryptophan residue. CDR-L2 begins at approximately the 16th residue after the end of CDR-L1 and consists of approximately 7 residues. CDR-L3 begins at approximately the 33rd residue after the end of CDR-L2 (i.e., after the cysteine residue); it consists of approximately 7 to 11 residues and ends at sequence F or WGXG, where X is any amino acid.
[0045] The antibodies disclosed herein can be derived from any animal source, including birds and mammals. Preferably, the antibodies are human, mouse, donkey, rabbit, goat, guinea pig, camel, llama, horse, or chicken antibodies. In another embodiment, the variable region can be derived from condricthoids (e.g., from sharks).
[0046] As used herein, the term "heavy chain constant region" includes an amino acid sequence derived from the immunoglobulin heavy chain. A polypeptide containing a heavy chain constant region comprises at least one of the following: a CH1 domain, a hinge (e.g., upper, middle, and / or lower hinge region) domain, a CH2 domain, a CH3 domain, or variants or fragments thereof. For example, an antigen-binding polypeptide for use in this disclosure may comprise: a polypeptide chain containing a CH1 domain; a polypeptide chain containing at least a portion of a CH1 domain, a hinge domain, and a CH2 domain; a polypeptide chain containing both a CH1 domain and a CH3 domain; a polypeptide chain containing at least a portion of a CH1 domain, a hinge domain, and a CH3 domain; or a polypeptide chain containing at least a portion of a CH1 domain, a hinge domain, a CH2 domain, and a CH3 domain. In another embodiment, the polypeptide of this disclosure comprises a polypeptide chain containing a CH3 domain. Furthermore, antibodies for use in this disclosure may lack at least a portion of the CH2 domain (e.g., all or part of the CH2 domain). As described above, those skilled in the art will understand that the heavy chain constant regions can be modified to differ in amino acid sequence from naturally occurring immunoglobulin molecules.
[0047] The heavy chain constant regions of antibodies disclosed in this paper can be derived from different immunoglobulin molecules. For example, the heavy chain constant regions of peptides can contain components derived from IgG. l The molecule contains the CH1 domain and a hinge region derived from the IgG3 molecule. In another example, the heavy chain constant region may contain a portion derived from IgG. l The heavy chain portion is derived from the hinge region of the IgG3 molecule. In another example, the heavy chain portion may contain components derived from IgG. l Molecules and chimeric hinges derived from IgG4 molecules.
[0048] As used herein, the term "light chain constant region" includes an amino acid sequence derived from the antibody light chain. Preferably, the light chain constant region comprises at least one of a constant κ domain or a constant λ domain.
[0049] A "light chain-heavy chain pair" refers to a combination of light and heavy chains that can form a dimer through disulfide bonds between the CL domain of the light chain and the CH1 domain of the heavy chain.
[0050] As previously described, the subunit structures and three-dimensional conformations of constant regions of various immunoglobulin classes are well known. As used herein, the term "VH domain" includes the amino-terminal variable domain of the immunoglobulin heavy chain, and the term "CH1 domain" includes the first (amino-terminal) constant region domain of the immunoglobulin heavy chain. The CH1 domain is adjacent to the VH domain and is located at the amino terminus of the hinge region of the immunoglobulin heavy chain molecule.
[0051] As used herein, the term "CH2 domain" encompasses the heavy chain molecule portion extending from approximately residue 244 to residue 360 of, for example, an antibody, using conventional numbering schemes (residues 244 to 360, Kabat numbering system; and residues 231 to 340, EU numbering system; see Kabat et al., US Dept. of Health and Human Services, "Sequences of Proteins of Immunological Interest" (1983). The CH2 domain is unique in that it does not pair tightly with another domain. Instead, two N-linked branched sugar chains are inserted between the two CH2 domains of the intact native IgG molecule. The CH3 domain is also well-documented, extending from the CH2 domain of the IgG molecule to the C-terminus and containing approximately 108 residues.
[0052] As used herein, the term "hinge region" refers to the portion of the heavy chain molecule that connects the CH1 and CH2 domains. This hinge region contains approximately 25 residues and is flexible, allowing the two N-terminal antigen-binding regions to move independently. The hinge region can be further subdivided into three distinct domains: the upper, middle, and lower hinge domains (Roux et al., J. Immunol 161:4083 (1998)).
[0053] As used herein, the term "disulfide bond" refers to a covalent bond formed between two sulfur atoms. The amino acid cysteine contains a thiol group that can form a disulfide bond or bridge with a second thiol group. In most naturally occurring IgG molecules, the CH1 and CK regions are linked by disulfide bonds, and the two heavy chains are linked by two disulfide bonds at positions corresponding to 239 and 242 (positions 226 or 229 in the EU numbering system) using the Kabat numbering system.
[0054] As used herein, the term "chimeric antibody" will be understood to refer to any antibody in which the immune-reactive region or site is derived from or originates from a first species and the constant region (which, according to this disclosure, may be whole, partial, or modified) is derived from a second species. In some embodiments, the target-binding region or site will be derived from a non-human source (e.g., mouse or primate) and the constant region will be human.
[0055] As used in this paper, the "percentage of humanization" is calculated by subtracting the number of framework amino acid differences (i.e., non-CDR differences) between the humanized domain and the germline domain from the total number of amino acids, then dividing by the total number of amino acids and multiplying by 100.
[0056] "Specific binding" or "specific to" generally refers to an antibody binding to an epitope via its antigen-binding domain, and this binding requires some complementarity between the antigen-binding domain and the epitope. According to this definition, an antibody is considered to "specifically bind" to an epitope when it binds to that epitope more readily than to a random, unrelated epitope. The term "specific" is used herein to define the relative affinity of an antibody for a given epitope. For example, antibody "A" may be considered to have higher specificity for a given epitope than antibody "B," or antibody "A" may be considered to bind to epitope "C" with higher specificity than it binds to related epitope "D."
[0057] As used herein, the term “treatment” refers to both therapeutic treatment and preventative or defensive measures aimed at preventing or mitigating (alleviating) undesirable physiological changes or disorders (such as cancer progression). Beneficial or desired clinical outcomes include, but are not limited to, reduction of detectable or undetectable symptoms, reduction of disease severity, stabilization of disease status (i.e., no worsening), delay or slowing of disease progression, improvement or mitigation of disease status, and (partial or complete) remission. “Treatment” can also mean prolonged survival compared to expected survival without treatment. Those who require treatment include those who already have a condition or disorder, those who are susceptible to a condition or disorder, or those who need prevention of a condition or disorder.
[0058] "Subject" or "individual" or "animal" or "patient" or "mammal" means any subject on whom a diagnosis, prognosis or treatment is expected, particularly a mammalian subject. Mammal subjects include humans, livestock, farm animals, as well as zoo animals, sporting animals or pet animals (e.g., dogs, cats, guinea pigs, rabbits, rats, mice, horses, cows, dairy cows, etc.).
[0059] As used herein, phrases such as “patient in need of treatment” or “subject in need of treatment” include subjects (e.g., mammalian subjects) who will benefit from administration of the antibody or composition disclosed herein for, for example, detection, diagnostic procedures and / or treatment.
[0060] Anti-SLC34A2 antibody Therefore, according to one embodiment of this disclosure, an ADC comprising an antibody capable of binding to SLC34A2 and an antigen-binding fragment thereof is provided. Exemplary antibodies include those of 30H9B8F9 (mouse antibodies) and humanized antibodies listed in Table 2. Antibodies comprising the same CDR as described herein are also included. In some embodiments, the disclosed antibodies and fragments include antibodies and fragments binding to the same epitopes as those shown herein, as well as antibodies and fragments competing with the antibodies and fragments of this disclosure for binding to SLC34A2.
[0061] According to one embodiment of this disclosure, an antibody or antigen-binding fragment thereof is provided, comprising heavy chain and light chain variable domains having the CDR regions disclosed herein, and their bioequivalents.
[0062] In one embodiment, the CDR is a CDR of 30H9B8F9 or its humanized counterpart, as illustrated in Table 2A. In one embodiment, VH CDR1 comprises the amino acid sequence of SEQ ID NO: 3 or a variant thereof having one, two, or three deletions, additions, substitutions, or combinations thereof; VH CDR2 comprises the amino acid sequence of SEQ ID NO: 4 or 9 or a variant thereof having one, two, or three deletions, additions, substitutions, or combinations thereof; VH CDR3 comprises the amino acid sequence of SEQ ID NO: 5 or a variant thereof having one, two, or three deletions, additions, substitutions, or combinations thereof; VL CDR1 comprises the amino acid sequence of SEQ ID NO: 6 or a variant thereof having one, two, or three deletions, additions, substitutions, or combinations thereof; VLCDR2 comprises the amino acid sequence of SEQ ID NO: 7 or a variant thereof having one, two, or three deletions, additions, substitutions, or combinations thereof; and VL CDR3 comprises the amino acid sequence of SEQ ID NO: 8 or a variant thereof having one, two, or three deletions, additions, substitutions, or combinations thereof.
[0063] As shown in the experimental examples, the VH CDR2 (SEQ ID NO: 9) of 30H9B8F9 contains an NG dipeptide, which may undergo post-translational modification (PTM). Therefore, an N=>S mutation is performed to prevent such PTM, and the mutated VH CDR2 is referred to as the PTM-derisked CDR. However, experimental data have demonstrated that the PTM-derisked version is just as effective as the original version.
[0064] In one embodiment, VH CDR1 comprises the amino acid sequence of SEQ ID NO: 3, VH CDR2 comprises the amino acid sequence of SEQ ID NO: 4, VH CDR3 comprises the amino acid sequence of SEQ ID NO: 5, VL CDR1 comprises the amino acid sequence of SEQ ID NO: 6, VL CDR2 comprises the amino acid sequence of SEQ ID NO: 7, and VL CDR3 comprises the amino acid sequence of SEQ ID NO: 8. In another embodiment, VH CDR1 comprises the amino acid sequence of SEQ ID NO: 3, VH CDR2 comprises the amino acid sequence of SEQ ID NO: 9, VH CDR3 comprises the amino acid sequence of SEQ ID NO: 5, VL CDR1 comprises the amino acid sequence of SEQ ID NO: 6, VL CDR2 comprises the amino acid sequence of SEQ ID NO: 7, and VL CDR3 comprises the amino acid sequence of SEQ ID NO: 8.
[0065] In some embodiments, antibodies and fragments comprising the same CDR as 30H9B8F9 or its humanized counterpart are also provided. In some embodiments, the disclosed antibodies and fragments include antibodies or fragments that bind to the same epitope as 30H9B8F9 or its humanized counterpart, and antibodies or fragments that compete with either of them for binding to SLC34A2.
[0066] In some embodiments, the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1 (mouse or chimeric) and 10 to 13 (humanized), or a peptide having at least 90% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NO: 1 (mouse or chimeric) and 10 to 13 (humanized).
[0067] In some embodiments, the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 2 (mouse or chimeric) and 14 to 17 (humanized), or a peptide having at least 90% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NO: 2 (mouse or chimeric) and 14 to 17 (humanized).
[0068] In some embodiments, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 11, and the light chain variable region comprises the amino acid sequence of any one of SEQ ID NO: 14 to 17. In some embodiments, the heavy chain variable region comprises the amino acid sequence of any one of SEQ ID NO: 10 to 13, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 14. In some embodiments, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 11, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 14.
[0069] It should be understood that CDRs can be modified to include CDRs with one, two, or three amino acid additions, deletions, and / or substitutions. In some embodiments, substitutions can be conservative substitutions.
[0070] "Conservative amino acid substitution" is the substitution in which an amino acid residue is replaced by an amino acid residue having a similar side chain. Families of amino acid residues with similar side chains are defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), β-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Therefore, non-essential amino acid residues in immunoglobulin peptides are preferably replaced by another amino acid residue from the same side chain family. In another embodiment, a string of amino acids can be replaced by a structurally similar string that differs in sequence and / or composition from members of the side chain family.
[0071] Those skilled in the art will also understand that the antibodies disclosed herein can be modified to differ in amino acid sequence from the naturally occurring binding polypeptides from which they are derived. For example, the polypeptide or amino acid sequence derived from the specified protein can be similar, for example, having a certain percentage of identity with the starting sequence, such as 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identity with the starting sequence.
[0072] Depending on the specific implementation, the antibody is a humanized antibody. The humanized form of a non-human (e.g., mouse) antibody is a chimeric molecule of an immunoglobulin, immunoglobulin chain, or fragment thereof (e.g., Fv, Fab, Fab', F(ab')2, or other antigen-binding sequence of the antibody) containing a minimal sequence derived from a non-human immunoglobulin. Humanized antibodies include human immunoglobulins (receptor antibodies) in which residues forming the complementarity-determining region (CDR) of the receptor are replaced by residues from a CDR of a non-human species (donor antibody) (e.g., mouse, rat, or rabbit) possessing the desired specificity, affinity, and capacity. In some cases, Fv framework residues of a human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also contain residues that are not present in the receptor antibody or in the introduced CDR or framework sequence. Typically, humanized antibodies will contain substantially all of at least one, usually two, variable domains, wherein all or substantially all of the CDR regions correspond to the CDR regions of non-human immunoglobulins, and all or substantially all of the FR regions are FR regions of the human immunoglobulin common sequence. Humanized antibodies preferably also contain at least a portion of the immunoglobulin constant region (Fc), typically at least a portion of the human immunoglobulin constant region (Jones et al., Nature, 321: 522-525 (1986); Riechmann et al., Nature, 332: 323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2: 593-596 (1992)).
[0073] In some implementations, the antibodies provided herein also include a heavy chain constant region, a light chain constant region, an Fc region, or a combination thereof.
[0074] The Fc region can be engineered to enhance effector function. IgG antibodies can induce direct antitumor effects by generating indirect antitumor effects through Fc-mediated effector functions that bind to other immune cells or killing mechanisms. As used herein, "effector function" or "antibody effector function" refers to the biological activity resulting from the binding of an antibody's Fc region to its effector (e.g., the C1 complex and Fc receptor (FcγRIIa or FcγRIIIa)). Exemplary effector functions include: complement-dependent cytotoxicity (CDC) induced by the interaction of the antibody with C1q on the C1 complex; antibody-dependent cell-mediated cytotoxicity (ADCC) induced by the binding of the antibody's Fc region to Fc receptors on effector cells; and antibody-dependent cell-mediated phagocytosis (ADCP), in which non-specific cytotoxic cells expressing FcγR recognize antibodies bound to target cells, subsequently causing phagocytosis of the target cells. Among the four IgG subclasses, IgG1 and IgG3 induce the strongest Fc effector functions. However, because IgG1 has the longest half-life and is more stable than IgG3, most therapeutic antibodies with Fc-mediated functions are IgG1 isotypes.
[0075] In some embodiments, the antibody or antigen-binding fragment thereof provided herein is an isotype of IgG1, IgG2, IgG3, or IgG4. In some embodiments, the antibody or antigen-binding fragment thereof is an isotype of IgG1. In some embodiments, the antibody or antigen-binding fragment thereof is human IgG1.
[0076] In some embodiments, the Fc region of the antibody provided herein is engineered to enhance effector function (e.g., ADCC or CDC). Various methods (primarily Fc mutations) can be found to enhance Fc-mediated effector function, such as those described in PCT disclosures WO2007024249A2 and WO2011044368A1, the entire contents of which are incorporated herein by reference. In some embodiments, the Fc region is engineered to include the S298A / E333A / K334A mutation in human IgG1. Such combinations of Fc mutations have been reported to enhance binding to FcγRIIIa, thereby enhancing ADCC (see Shields RL et al., J. Biol. Chem 276:6591-6604 (2001)).
[0077] Antibody drug conjugates This disclosure provides anti-SLC34A2 antibody-drug conjugates that bind specifically to the human SLC34A2 protein and significantly inhibit the proliferation of cells expressing NaPi2b. Such ADCs (e.g., 30H9B8F9.p1.z5-MMAE, 30H9B8F9.p1.z5-Dxd, and 30H9B8F9.p1.z5-LM-D01) have shown in vivo antitumor activity in various tumor models.
[0078] Antibody-drug conjugates (ADCs) comprise an antibody or its antigen-binding fragment conjugated to a drug (or payload) via a linker. The drug can be linked to the antibody via cysteine or lysine residues on the antibody. ADCs can be constructed chemically, for example, by utilizing pre-existing lysine or cysteine residues through random conjugation reactions such as amide conjugation (of lysine) and thiol conjugation (of cysteine). Active carboxylic acid esters (when available in the linker) are used to link the payload to lysine residues on the antibody. The primary amine in Lys readily reacts with the N-hydroxysuccinimide (NHS) ester introduced into the linker to form a stable amide. A typical IgG1 antibody molecule has approximately 90 Lys residues, of which approximately 30 can be modified for conjugation, meaning that 1 to 30 payloads can be covalently conjugated to the antibody. As for cysteine, after reduction, the disulfide bond can be transformed to expose free cysteine residues that can be used for conjugation reactions such as Michael addition, disulfide bond formation, and α-halocarbonyl alkylation.
[0079] ADCs can also be constructed via enzymatic methods, such as site-specific conjugation. Site-specific conjugation includes the introduction of engineered reactive cysteine residues, disulfide bond rebridging, non-natural amino acids, enzyme-assisted ligation or glycan reconstruction, sugar conjugation, or click chemistry. Details of conjugation methods can be found in the art, for example, Fu et al., Signal Transduction and Targeted Therapy 7:93 (2022).
[0080] The drug-antibody ratio (DAR) of an ADC can be greater than 2, greater than 4, greater than 6, greater than 8, greater than 10, greater than 16, greater than 20, or greater than 30. In some embodiments, the drug-antibody ratio (DAR) can be 1 to 30, 1 to 20, 1 to 16, 1 to 10, 1 to 8, for example, 4 to 8 or 2 to 4. In some embodiments, the drug-antibody ratio (DAR) can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 16, 20, or 30. In some embodiments, the DAR is homogeneous.
[0081] Drug linker compounds can contain linkers that are either uncuttable or cuttable. Cuttable linkers mainly include enzyme-cuttable linkers and chemically sensitive linkers.
[0082] Uncleavable linkers consist of stable bonds that resist protein hydrolysis and ensure greater plasma stability. The mechanism of action of uncleavable linkers is based on the internalization of the ADC complex, followed by the degradation of mAb components in lysosomes, thereby releasing cytotoxic drugs capable of killing tumor cells. They do not release cytotoxic agents at off-target sites and therefore do not harm healthy cells. Uncleavable linkers are classified into two groups: thioether or maleimide hexanoyl (MC). Examples of uncleavable linkers include, but are not limited to, 4-maleimide methylcyclohexane-1-carboxylate (MCC), succinimide-4-(N-maleimide methyl)cyclohexane-1-carboxylate (SMCC), maleimide hexanoyl (MC), and p-carboxycyclohexylmethylmaleimide.
[0083] Cleavable adapters mainly include chemically sensitive adapters and enzyme-cleavable adapters. Chemically sensitive adapters are usually cleaved by environmental differences (such as redox potential and pH), while enzyme-cleavable adapters are cleaved by specific enzymes in response to extracellular and intracellular environments.
[0084] Chemically sensitive connectors include, but are not limited to, pH-sensitive connectors and glutathione-sensitive disulfide connectors. (Khongorzul et al., Mol Cancer Res; 18(1) (2020)).
[0085] pH-sensitive adapters are a group of adapters that are sensitive to acidic environments but stable in alkaline environments (e.g., systemic circulation), such as hydrazone-based adapters. A successful example of an ADC design using pH-sensitive adapters is the IMMU-110, which consists of a humanized anti-CD74 mAb conjugated with doxorubicin via an acid-labile hydrazone.
[0086] Glutathione-sensitive disulfide linkers utilize the difference in reduction potential between the cytoplasm and plasma. High concentrations of glutathione can be found in cancer cells compared to normal cells. Glutathione-sensitive linkers are stable in the bloodstream and can be specifically cleaved by the elevated intracellular concentration of glutathione in tumor cells, thereby releasing the active drug from a non-toxic prodrug at the tumor site (see above).
[0087] Enzyme-cleavable adapters include, but are not limited to, peptide-based adapters, β-glucuronide-based adapters, and phosphate-based adapters.
[0088] Peptide-based linkers (also known as protease-sensitive linkers) are the most commonly used ADC linkers. These linkers can be cleaved extracellularly and / or intracellularly by specific proteases. For intracellular cleavage, because tumor cells exhibit high expression of lysosomal proteases (such as cathepsin B) compared to normal cells, protease-sensitive peptide linker ADCs selectively bind and transform into cancer cells via receptor-mediated endocytosis. Peptide linkers are stable in systemic circulation and release drugs only in target cells (see above). Examples are valine-citrulline (VC or Val-Cit), valine-alanine (VA), phenylalanine-lysine (PL), and glycine-glycine-phenylalanine-glycine (GGFG).
[0089] The β-glucuronide-based linker is recognized and hydrolyzed by β-glucuronidase or β-galactosidase to release the drug, and both β-glucuronidase and β-galactosidase are enriched in lysosomes and tumor necrosis zones. β-glucuronidase is inactive at physiological pH (circulatory) but active at lysosomal pH. This selective site of action allows for the cleavage of the glycosidic bond in the β-glucuronidase-sensitive β-glucuronide linker, thereby enabling the selective release of cytotoxic payloads (see above).
[0090] Phosphate-based linkers are a class of enzyme-cleavable linkers that specifically target target enzymes within lysosomal compartments. These linkers target pyrophosphatases and acid phosphatases, which hydrolyze pyrophosphates and terminal monophosphates into their respective alcohols.
[0091] Parts that can be introduced as part of a linker to facilitate drug-linker or antibody-linker linkage include maleimide hexanoyl, maleimide-hexanoyl (MC) moiety, maleimide-methylene-cyclohexylcarbonyl moiety spacer, maleimide propionyl (MP), p-aminobenzylcarbamate (PAB) spacer, p-aminobenzyloxycarbamate (PABC) spacer, aminomethoxymethylenecarbonyl (-NH-CH2-O-CH2-CO-) spacer, 4-(4'-acetylphenoxy)butyric acid moiety, acylhydrazide (-CO-NH-NH2) and thiol (-SH) moiety, Lys-PABC, PEG chain, and PEG8.
[0092] Examples of connectors include, but are not limited to, succinimide-4-(N-maleimidemethyl)cyclohexane-1-carboxylate (SMCC), sulfonyl-SMCC, MC-VC-PABC, CL2A, MC-GGFG, MC, MC-PEG8-GGFG, MC-PEG8-GGFG-PAB, or MP-PEG8-VA-PABC.
[0093] The drug or payload can be a cytotoxin, a therapeutic peptide, or a polypeptide.
[0094] The peptide or polypeptide can be any peptide or polypeptide having therapeutic properties (e.g., analgesic, antidiabetic, antitumor, or antiviral activity). Additionally or alternatively, the drug preferably contains an amine group, a thiol group, or a carboxylic acid group, as these types of groups provide ideal sites for the conjugation of the drug with the connectors of this disclosure. Examples of biological agents are Pseudomonas aeruginosa exotoxin PE38, diphtheria toxin, Staphylococcus aureus enterotoxin A / E-120, Shiga toxin, ricin, and urease.
[0095] Cytotoxins, once released from ADCs, are activated in the cytoplasm of tumor cells, thereby destroying them. There are two main types of cytotoxins that can be used in ADC design: microtubule disruptors (e.g., auristatin and maytanyl alkaloids) and DNA damage agents (e.g., chalcogenide, benzodiazepines, and doxorubicin). Examples include, but are not limited to: auristatin, maytanyl alkaloids, benzodiazepines, microtubule-lysin, benzodiazepines, chalcogenide, ixenotac, irinotecan (SN38), doxorubicin, anthracycline, pyrrolobenzodiazepines (PBD), TLR agonists, and STING agonists.
[0096] Auristatins are synthetic antitumor agents derived from the natural product saliton toxin 10. They block the microtubule polymerization process, leading to cell cycle arrest and apoptosis. Examples include monomethylaurestatin E (MMAE) and monomethylaurestatin F (MMAF).
[0097] Maytansine alkaloids are isolated from maytansine (a benzo[a] macrolide). These drugs inhibit microtubule polymerization. Examples include DM1 and DM4.
[0098] Kazimidic acid is a type of fungus derived from Micromonospora echinococcosis (… Micromonospora echinospora Kazimidic acid is an enediyne-based antitumor antibiotic. It recognizes the minor groove of DNA, preventing DNA replication and thus causing mitotic arrest and cell death. An example is N-acetylkazimidic acid, a derivative of kazimidic acid.
[0099] Betamicil is derived from bacteria of the genus Streptomyces (Streptomyces spp.) Streptomyces (This refers to a natural product derivative extracted from a strain of bacteria.) Betainecin is another type of DNA minor groove binding alkylating agent. These drugs exert their effect by binding to the minor groove of DNA, subsequently causing irreparable alkylation of the DNA, thus disrupting the architecture and structural integrity of nucleic acids.
[0100] Doxorubicin works by inserting into DNA to inhibit DNA synthesis. One example is IMMU-110.
[0101] Iciticon is derived from the Chinese tree Camptotheca acuminata (Camptotheca sinensis). Camptotheca acuminataEcinotecan is a synthetic derivative of the natural cytotoxin camptothecin, isolated from [a specific organism / organism]. Like camptothecin, eccinotecan binds to the topoisomerase 1-DNA complex, preventing DNA rejoining, leading to the accumulation of DNA strand breaks and ultimately cell death. Examples of eccinotecan are DX-8951f and DXd. 7-Ethyl-10-hydroxycamptothecin (SN-38) is also a derivative of camptothecin.
[0102] Other examples of cytotoxins include, but are not limited to, macrocyclic ketone analogs, topoisomerase inhibitors, tubulolysin A, camptothecin, DGN462, ambestatin 269, atrazomycin, SG3199 / SCX, IRDye® 700DX, TLR7 / 8 agonists, and diABZI STING agonist-2.
[0103] Cytotoxins can be chemotherapeutic agents, which can be classified according to their mechanism of action into groups such as the following: -Antimetabolites / anticancer agents (e.g., pyrimidine analogues fluorouridine, capecitabine, and cytarabine); -Purine analogues, folic acid antagonists and related inhibitors; - Antiproliferative / antimitotic agents, including natural products (e.g., vinblastine, vincristine) and microtubules (e.g., taxanes (paclitaxel, docetaxel), vinblastin, nocodazole, epothilone, vinorelbine). ® And epipodophyllotoxin (etoposide, teniposide); DNA damaging agents (e.g., actinomycin, acridine, busulfan, carboplatin, chlorambucil, cisplatin, cyclophosphamide) ® Actinomycin D, daunorubicin, doxorubicin, epirubicin, ifosfamide, melphalan, nitrogen mustard, mitomycin, mitoxantrone, nitrosourea, procarbazine, paclitaxel, docetaxel, teniposide, etoposide, and triethylene thiophosphoramide). - Antibiotics (such as actinomycin D, daunorubicin, doxorubicin, idarubicin, anthracycline, mitoxantrone, bleomycin, procainox (scintillans), and mitomycin); -Enzymes (such as L-asparaginase, which systemically metabolizes L-asparagine and causes cells that cannot synthesize asparagine to lose it). -Antibacterial agents; - Antiproliferative / antimitotic alkylating agents (e.g., nitrogen mustard cyclophosphamides and their analogues (melphalan, chlorambucil, hexamethylmelamine and thiotepa), alkylnitrosoureas (carmustine) and their analogues, streptozotocin and triazine (dacarbazine)); - Antiproliferative / antimitotic antimetabolites (e.g., folic acid analogues (methotrexate)); - Platinum coordination complexes (cisplatin, oxaliplatin and carboplatin), procarbazine, hydroxyurea, mitotane and ammonia glutathione; - Hormones, hormone analogs (estrogens, tamoxifen, goserelin, bicalutamide, and nilumid), aromatase inhibitors (letrozole and anastrozole); - Anticoagulants (such as heparin, synthetic heparin salts and other thrombin inhibitors); - Fibrinolytic agents (such as tissue plasminogen activator, streptokinase, urokinase, aspirin, dipyridamole, ticlopidine, and clopidogrel); -Anti-migration agent; - Antisecretory agents (breveldin); -Immunosuppressants tacrolimus, sirolimus, azathioprine, and mycophenolate mofetil; - Compounds (TNP-470, genistein) and growth factor inhibitors (vascular endothelial growth factor inhibitor and fibroblast growth factor inhibitor). -Angiotensin receptor blockers, nitric oxide donors; -Antisense oligonucleotides; - Antibodies (such as trastuzumab and rituximab); - Cell cycle inhibitors and differentiation inducers (e.g., retinoic acid); - Inhibitors, topoisomerase inhibitors (doxorubicin, daunorubicin, actinomycin D, eniposide, epirubicin, etoposide, idarubicin, irinotecan, mitoxantrone, topotecan and irinotecan) and corticosteroids (cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisone and prednisolone); - Growth factor signal transduction kinase inhibitors; - Dysfunction inducers; -Toxins (such as cholera toxin, ricin, Pseudomonas exotoxin, Bordetella pertussis adenylate cyclase toxin, diphtheria toxin, and caspase activator). - and chromatin.
[0104] Other examples of chemotherapy agents include: - Alkylating agents (e.g., thiotepa and cyclophosphamide) ® )); -Alkyl sulfonates (e.g., busulfan, indomethacin, and piperazine); -Zalaziridines (e.g., benzodopa, carboquinone, meturedopa, and uredopa); - Emylerumine and memylamelamine (including alfretamine, triemylenemelamine, triemylphosphonamide, triemylthiophosphonamide, and triemylolomelamine); - Acetogenin (especially blatazine and blatazine ketone); - Camptothecin (including its synthetic analogue topotecan); - Lichenin; - Callystatin; -CC-1065 (including its synthetic analogues of adoresin, calceresin and pyresin); - Cryptophytic substances (especially cryptophytic 1 and cryptophytic 8); -Sea slug toxin; - Betamethasone (including synthetic analogues KW-2189 and CBI-TMI); -Eleutherobin; -Pancradin; -Cynocoral alcohol; -Spongistatin; - Nitrogen mustards (e.g., chlorambucil, naphthylambucil, cyclophosphamide, estradiol, ifosfamide, dichloromethyldiethylamine, dichloromethyldiethylamine hydrochloride, melphalan, neonitrogen mustard, benzylmustine, prednimustine, trazophosphatide, and uracil mustard); - Nitrosoureas (e.g., carmustine, chloramphenicol, formustine, lomustine, nimustine, and ramustine); - Antibiotics (e.g., enediyne antibiotics (e.g., kazimycin, especially kazimycin γII and kazimycin φI1), danendomycin (including danendomycin A), bisphosphonates (e.g., clophosphonates), esperamycin, neomycin chromophores and related pigment proteins, enediyne antibiotic chromophores, aclarubicin, actinomycin, diazoserine, bleomycin, actinomycin C, carabicin, carrninomycin, carcinomatin, chromomycin, actinomycin D, daunorubicin) Doxorubicin, ditorubicin, 6-diazo-5-oxo-L-leucine, doxorubicin (including morpholino doxorubicin, cyanomorpholino doxorubicin, 2-pyrrolinoline doxorubicin and deoxydoxorubicin), epirubicin, isorubicin, idarubicin, maseromycin, mitomycin (e.g., mitomycin C), mycophenolic acid, nogamycin, oligomycin, pepromycin, pofibromycin, puromycin, quelamycin, rodorubicin, streptomycin, streptozotocin, tuberculin, ubenmexicin, fenestrated statin, zorubicin); -Antimetabolites (e.g., methotrexate and 5-fluorouracil (5-FU)); - Folic acid analogues (such as dmodetine, methotrexate, pteroxate and trimethoprim); -Purine analogues (e.g., fludarabine, 6-mercaptopurine, nitrothioguanine, and thioguanine); -Pyrimidine analogues (e.g., ancitabine, azacitidine, 6-azauridine, carmoflu, cytarabine, dideoxyuridine, deoxyfluorouridine, enoxabin, and fluorouridine); - Androgens (such as capetorone, drotalbutone propionate, cyclothiosterol, meandrolone, and testosterone); - Anti-adrenergic drugs (such as aminoglutide, mitotane and triplostertan). - Folic acid replacement therapy (e.g., frolinic acid); - Trichothecetes (especially T-2 toxin, wartycin A, roridin A, and serpentin); - Taxanes (e.g., paclitaxel (TAXOL) ® ) and TAXOTERE ® )); - Platinum analogues (e.g., cisplatin, carboplatin); - Acetaldehyde lactone; Aldolphosphatidylglycoside; Aminolevulinic acid; Eniruracil; Acridine; Hebsil; Bisaccharin; Edatraxa; Defofamine; Colchicine; Diacinone; Elformthine; Elimethicone; Epotoxin; Etoglobulin; Gallium nitrate; Hydroxyurea; Lentinan; Leucovorin; Lonidadine; Maytansine alkaloids (e.g., Maytansine and Ansericin); Mitoguanidine; Mitoantrone; Mopiperol; Nitracrid; Pentostatin; Methamidophos; Pirarubicin; Loxoantrone; Fluoropyrimidine; Leucovorin; Podophyllotoxin; 2-Ethylhydrazine; Procarbazine; Polysaccharide-K (PSK); Razosen; Rhizomycin; Cizonan; Germonospiramine; Alternaria solanilic acid; Triaminoquinone; 2,2',2''-Trichlorotriethylamine; Urethane; Vinpocetine; Dacarbazine; Mannomustine; Dibromomannitol; Dibromoeugenol; Piperobromide; Gacytosine; Cytarabine (“Ara-C”); Cyclophosphamide; Thiopeta; Chlorobenzine; Gemcitabine ® ); 6-Thioguanine; mercaptopurine; methotrexate; vincristine; platinum-based drugs; etoposide (VP-16); ifosfamide; mitroxantrone; vancristine; vinorelbine ® ); Norfloxacin; Teniposide; Idatraxa; Daunorubicin; Aminopterin; Xeloda; Ibandronic acid; CPT-11; Topoisomerase inhibitor RFS 2000; Difluoromethylornithine (DFMO); Retinoids (e.g., retinoic acid); Capecitabine; FOLFIRI (fluorouracil, folinic acid, and irinotecan); - and pharmaceutically acceptable salts, acids or derivatives of any of the above substances.
[0105] In certain embodiments of this disclosure, the drug and the linker form a drug linker compound. In some embodiments, the drug linker compound may be oxazolidin (a chachiomycin derivative, see U.S. Patent No. 5,773,001), vedotin (MC-VC-PABC-MMAE, see U.S. Patent No. 7,659,241), maltodine (MC-MMAF, see U.S. Patent No. 7,498,298), emmetine (SMCC-DM1, see U.S. Patent No. 5,208,020), delutecan (MC-GGFG-DXd, see U.S. Patent No. 10,195,288), goxatecan (CL2A-SN38, see U.S. Patent No. 8,420,086), or tercilin (MP-PEG8-VA-PABC-SG3199 / SCX, see U.S. Patent No. 9,889,207), the full text of which is incorporated herein by reference.
[0106] Other examples of drug linker compounds include parzetoxin (pasudotox) (PE38), solatanine (DM4), lavtanine (DM4), and metanine (DM1).
[0107] In some embodiments of this disclosure, the drug connector compound comprises LM-D01 having Formula I: (I).
[0108] In some embodiments of this disclosure, the drug connector compound comprises LM-D02 having formula II: (II).
[0109] In some embodiments of this disclosure, the drug connector compound comprises LM-D03 having formula III: (III).
[0110] In some embodiments of this disclosure, the drug connector compound comprises vedotin having formula IV: (IV).
[0111] In some embodiments of this disclosure, the drug connector compound comprises derutin having formula V: (V).
[0112] In some embodiments of this disclosure, the drug connector compound comprises oxazolidin having formula VI: (VI).
[0113] In some embodiments of this disclosure, the drug connector compound comprises maltodine having formula VII: (VII)
[0114] In some embodiments of this disclosure, the drug connector compound comprises emmetaneline having formula VIII: (VIII).
[0115] In some embodiments of this disclosure, the drug connector compound comprises goxanotecan having formula IX: (IX).
[0116] In some embodiments of this disclosure, the drug connector compound comprises tercillin having the formula X: (X).
[0117] Treatment As described herein, the antibody-drug conjugates disclosed herein can be used in certain therapeutic and diagnostic methods.
[0118] This disclosure also relates to antibody-based therapies involving the administration of the ADC of this disclosure to a patient (e.g., an animal, mammal, or human) for the treatment of one or more of the conditions or symptoms described herein.
[0119] The ADC disclosed herein can also be used to treat or inhibit cancer. In some embodiments, cancer cells in a patient express or overexpress SLC34A2 / NaPi2b. As mentioned above, NaPi2b may be overexpressed in tumor cells, particularly in tumors of the stomach, pancreas, esophagus, ovary, and lung. Inhibition of SLC34A2 / NaPi2b has been shown to be useful for treating tumors.
[0120] Therefore, in some embodiments, methods for treating cancer in patients in need are provided. In one embodiment, the method involves administering an effective amount of the disclosed antibody to the patient. In some embodiments, at least one cancer cell (e.g., stromal cells) in the patient overexpresses SLC34A2 / NaPi2b.
[0121] In some implementations, cells are isolated from the cancer patient themselves. In other implementations, cells are provided by a donor or from a cell bank. When cells are isolated from cancer patients, unwanted immune responses can be minimized.
[0122] Non-limiting examples of cancer include bladder cancer, breast cancer, colorectal cancer, endometrial cancer, esophageal cancer, head and neck cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, pancreatic cancer, prostate cancer, and thyroid cancer. In some implementations, the cancer is one or more of stomach cancer, pancreatic cancer, esophageal cancer, ovarian cancer, and lung cancer.
[0123] The antibodies or variants or derivatives thereof disclosed herein can be used to treat, prevent, diagnose, and / or prognose other diseases or conditions associated with increased cell survival, including but not limited to the progression and / or metastasis of malignancies and related conditions such as leukemia (including acute leukemia (e.g., acute lymphoblastic leukemia, acute myeloid leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemia (e.g., chronic myeloid (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphoma (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenström macroglobulinemia, heavy chain disease, and solid tumors, including but not limited to sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, and liposarcoma. Sarcoma, chondrosarcoma, osteosarcoma, chordoma, angiosarcoma, endothelial sarcoma, lymphangioma, lymphangioendothelial sarcoma, synovoma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchial carcinoma, renal cell carcinoma, hepatocellular carcinoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, nephroblastoma, cervical cancer, testicular tumor, lung cancer, small cell lung cancer, bladder cancer, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pineal tumor, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma.
[0124] The specific dosage and treatment regimen for any particular patient will depend on a number of factors, including the specific ADC used, the patient's age, weight, general health condition, sex and diet, timing of administration, excretion rate, drug combination, and the severity of the specific disease being treated. The healthcare professional's judgment of these factors is within the realm of general technical expertise. The dosage will also depend on the individual patient to be treated, the route of administration, the type of formulation, the characteristics of the compound used, the severity of the disease, and the desired effect. The dosage used can be determined using principles of pharmacology and pharmacokinetics known in the art.
[0125] Methods of administration of ADCs include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. Antigen-binding peptides or compositions can be administered via any convenient route (e.g., by infusion or bolus, absorption through the epithelial or mucosal inner layer of the skin (e.g., oral mucosa, rectal and intestinal mucosa, etc.)) and can be administered with other bioactive agents. Therefore, pharmaceutical compositions containing the antigen-binding peptides of this disclosure can be administered orally, rectally, parenterally, intracerebrospinal, intravaginally, intraperitoneally, topically (e.g., by powder, ointment, drops, or transdermal patch), sublingually, or as oral or nasal sprays.
[0126] As used in this article, the term "parenteral" refers to administration methods including intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous, and intra-articular injections and infusions.
[0127] Administration can be systemic or local. Furthermore, it is desirable to introduce the antibodies of this disclosure into the central nervous system via any suitable route, including intraventricular and intrathecal injection; intraventricular injection can be facilitated, for example, by an intraventricular catheter connected to a reservoir (e.g., an Ommaya reservoir). Pulmonary administration can also be employed, for example, by using an inhaler or nebulizer and in combination with a nebulizing agent.
[0128] It is desirable to apply the ADC or composition of this disclosure topically to the area requiring treatment; this can be achieved, for example, but not limited to, local infusion during surgery, local application (e.g., in conjunction with postoperative wound dressing), by injection, by catheter, by suppository, or by implantation, said implant being a porous, non-porous, or gel-like material, including membranes (e.g., sialic acid membranes) or fibers. Preferably, when applying the proteins (including antibodies) of this disclosure, care must be taken to use materials that do not absorb proteins.
[0129] The amount at which the ADC of this disclosure will be effective in treating, inhibiting, and preventing immune or malignant diseases, conditions, or symptoms can be determined using standard clinical techniques. Additionally, in vitro assays may optionally be used to help identify the optimal dose range. The precise dose used in the formulation will also depend on the route of administration and the severity of the disease, condition, or symptom, and should be determined based on the physician's judgment and the individual patient's situation. The effective dose can be extrapolated from dose-response curves derived from in vitro or animal model testing systems.
[0130] As a general recommendation, the dosage of the ADC of this disclosure administered to patients is typically 0.1 mg / kg to 100 mg / kg patient body weight, 0.1 mg / kg to 20 mg / kg patient body weight, or 1 mg / kg to 10 mg / kg patient body weight. Generally, due to the immune response to exogenous peptides, human antibodies have a longer half-life in the human body than antibodies from other species. Therefore, lower doses of human antibodies and less frequent administration are generally possible. Furthermore, the dosage and frequency of administration of the ADC of this disclosure can be reduced by modifications (e.g., lipolysis) that enhance ADC uptake and tissue penetration (e.g., into the brain).
[0131] In another embodiment, the compositions of this disclosure are administered in combination with cytokines. Cytokines that can be administered with the compositions of this disclosure include, but are not limited to, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, anti-CD40, CD40L, and TNF-α.
[0132] In another embodiment, the compositions disclosed herein are administered in combination with other treatment or preventative measures (e.g., radiotherapy).
[0133] Composition This disclosure also provides pharmaceutical compositions. Such compositions comprise an effective amount of an ADC and an acceptable carrier. In some embodiments, the composition further comprises a second anticancer agent (e.g., an immune checkpoint inhibitor).
[0134] In one specific implementation, the term "pharmaceutical acceptable" means a substance approved by a federal or state regulatory agency or listed in the United States Pharmacopeia or other recognized pharmacopoeia for use in animals, and more particularly for human use. Furthermore, "pharmaceutical acceptable carrier" generally refers to any type of non-toxic solid, semi-solid, or liquid filler, diluent, encapsulating material, or formulation adjuvant.
[0135] The term "carrier" refers to a diluent, adjuvant, excipient, or solvent that is administered with the therapeutic agent. Such drug carriers can be sterile liquids, such as water and oils, including petroleum, animal, plant, or synthetic oils, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. Water is the preferred carrier when the drug composition is administered intravenously. Saline solutions, as well as glucose and glycerol solutions, can also be used as liquid carriers, particularly for injectable solutions. Suitable drug excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, skim milk powder, glycerin, propylene, ethylene glycol, water, ethanol, etc. If desired, the composition may also contain small amounts of wetting agents or emulsifiers, or pH buffers (e.g., acetates, citrates, or phosphates). Antimicrobial agents (e.g., benzyl alcohol or methylparaben); antioxidants (e.g., ascorbic acid or sodium bisulfite); chelating agents (e.g., EDTA); and agents for regulating tension (e.g., sodium chloride or glucose) may also be considered. These compositions can be in the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations, etc. Compositions can be formulated into suppositories using conventional binders and carriers (e.g., triglycerides). Oral formulations may contain standard carriers (e.g., pharmaceutical-grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, etc.). Examples of suitable drug carriers are described in EW Martin's Remington's Pharmaceutical Sciences, which is incorporated herein by reference. Such compositions will contain a therapeutically effective amount of an antigen-binding polypeptide (preferably in a purified form) and an appropriate amount of carrier to provide a form suitable for appropriate administration to the patient. The formulation should be suitable for the mode of administration. Parenteral formulations may be packaged in ampoules, disposable syringes, or multi-dose vials made of glass or plastic.
[0136] In one embodiment, the composition is formulated according to conventional methods to a pharmaceutical composition suitable for intravenous administration to humans. Typically, the composition for intravenous administration is a solution in a sterile isotonic buffer solution. If necessary, the composition may also contain a solubilizer and a local anesthetic (e.g., lidocaine) to relieve pain at the injection site. These components are typically provided individually or in combination in unit dosage forms, for example, as lyophilized powder or anhydrous concentrate in a sealed container (e.g., an ampoule or sachet) indicating the amount of active agent. When the composition is administered by infusion, it can be dispensed using an infusion bottle containing sterile pharmaceutical-grade water or saline. When the composition is administered by injection, a single ampoule of sterile water or saline for injection can be provided to allow for mixing of the components prior to administration.
[0137] The ADC disclosed herein can be formulated into neutral or salt forms. Pharmaceutically acceptable salts include salts that form with anions (e.g., salts derived from hydrochloric acid, phosphoric acid, acetic acid, oxalic acid, tartaric acid, etc.) and salts that form with cations (e.g., salts derived from sodium, potassium, ammonium, calcium, ferric hydroxide, isopropylamine, triethylamine, 2-ethylaminoethanol, histidine, procaine, etc.).
[0138] Example Example 1: Monoclonal antibody against human SLC34A2 The VH / VL sequences of the cloned mouse antibodies are provided in Table 1 below.
[0139] Table 1. VH / VL sequences of mouse antibody 30H9B8F9
[0140] The amino acid sequences of VH and VL from 30H9B8F9 were compared with available human Ig gene sequence databases to find the best-matching human germline Ig gene sequence overall. The CDR of the mouse antibody was then transplanted into the matching human sequence. cDNA was synthesized and used to generate the humanized antibody. Certain reversion mutations from the mouse antibody were then introduced back into the humanized antibody.
[0141] The amino acid sequences of humanized antibodies and PTM-derisked antibodies are provided in Table 2 below.
[0142] Table 2A. Humanized Sequences
[0143] Table 2B. CDR Sequences
[0144] Table 2C. Humanized Antibodies
[0145] Humanized / PTM-derisked antibodies can bind with high affinity to cells expressing human SLC34A2 (e.g., HEK293 / H_SLC34A2, OVCAR3, and RMG-1 cells). In further assays, the binding affinity of these antibodies to rhesus monkey / rat / mouse SLC34A2 was evaluated, and the results showed that these humanized / PTM-derisked antibodies retained high affinity. Another assay confirmed the potent ADCC-inducing activity of these humanized / PTM-derisked antibodies. Furthermore, 30H9B8F9.p1.z5 significantly outperformed the benchmarks BMK-01 (XMT-1536) or BMK-02 (RG-7599) in many respects, such as binding to human SLC34A2 on different cell types, cross-reactivity with SLC34A2 proteins from different species, and ADCC-inducing activity.
[0146] Example 2: Inhibition of human NaPi2b-expressing cells by ADC 30H9B8F9.p1.z5-MMAE, 30H9B8F9.p1.z5-Dxd, and 30H9B8F9.p1.z5-LM-D01 are derived antibody-drug conjugates (ADCs) conjugated to MMAE, Dxd, and the self-developed payload LM-D01, respectively. Mersana's ADC XMT-1536-MMAE was used as a reference. Human NaPi2b-expressing cell lines (human ovarian cancer cell lines OVCAR-3, RMG-1, and engineered cell lines NCI-H1975 / H_NaPi2b.#5 and NCI-H441 / H_NaPi2b.#5) were seeded in 96-well plates and treated with the appropriate concentration of ADC for 6 days. Cell viability was measured using CellTiter-Glo reagent. Luciferase activity was detected using Envison assay.
[0147] Figure 1 A to Figure 1 The results of D showed that these ADCs had strong killing activity against cell lines expressing human NaPi2b, and the inhibitory effect of 30H9B8F9.p1.z5-MMAE was higher than that of XMT-1536-MMAE.
[0148] Example 3. ADCs reduce tumor size in the OVCAR-3 tumor model The ADCs used for testing were antibody-drug conjugates (ADCs) derived from 30H9B8F9.p1.z5, which were conjugated to MMAE, Dxd, and the self-developed payload LM-D01, respectively. CB17-SCID mice carrying OVCAR-3 tumor cells were randomly assigned to groups (n=5 per group), and tumors were tested when the tumor size reached 80 mm. 3 Up to 100 mm3 It was administered intravenously (iv) on days 0, 7, and 14 post-treatment. Following ADC treatment, it demonstrated dose-dependent antitumor activity in the OVCAR-3-CDX model.
[0149] All ADCs effectively inhibited tumor growth in the OVCAR-3 model at various dosages. 30H9B8F9.p1.z5-LM-D01 was observed to have superior tumor-suppressive activity compared to 30H9B8F9.p1.z5-Dxd, and 3 mg / kg and 10 mg / kg of 30H9B8F9.p1.z5-LM-D01 showed complete tumor eradication in the CDX model. Figure 2 A). Weight fluctuations indicate that all treatments were well tolerated. Figure 2 B).
[0150] Example 4. ADC reduces tumor size in the NCI-H1975 / H_NaPi2b tumor model The ADCs used for testing were antibody-drug conjugates (ADCs) derived from 30H9B8F9.p1.z5, which were conjugated to MMAE, Dxd, and the self-developed payload LM-D01, respectively. BALB / c nude mice carrying the NCI-H1975 / H_NaPi2b cell line were randomly assigned to groups (n=5 per group), and tumors were tested when they reached a size of 80 mm. 3 Up to 100 mm 3 It was administered intravenously (iv) on days 0, 7, and 14 post-treatment. Following ADC treatment, it demonstrated dose-dependent antitumor activity in the NCI-H1975 / H_NaPi2b-CDX model.
[0151] 30H9B8F9.p1.z5-MMAE was observed to have superior tumor-suppressive activity compared to other ADCs, and 3 mg / kg of 30H9B8F9.p1.z5-MMAE and 30H9B8F9.p1.z5-LM-D01 showed complete tumor eradication in the CDX model. Figure 3 A). Weight fluctuations indicate that all treatments were well tolerated. Figure 3 B).
[0152]
[0153] This disclosure is not limited to the specific embodiments described herein, which are intended as a single illustration of various aspects of this disclosure, and any functionally equivalent compositions or methods are within the scope of this disclosure. It will be apparent to those skilled in the art that various modifications and variations can be made to the methods and compositions of this disclosure without departing from the spirit or scope of this disclosure. Therefore, this disclosure is intended to cover such modifications and variations, provided that such modifications and variations are within the scope of the appended claims and their equivalents.
[0154] All publications and patent applications mentioned in this specification are incorporated herein by reference to the extent that each individual publication or patent application is specifically and individually indicated to be incorporated herein by reference.
Claims
1. An antibody-drug conjugate comprising an antibody or antigen-binding fragment thereof conjugated to a drug, wherein the antibody or antigen-binding fragment thereof has binding specificity to human lysosome carrier 34A2 (SLC34A2) protein and comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises heavy chain complementarity-determining regions VH CDR1, VHCDR2, and VH CDR3, and the light chain variable region comprises light chain complementarity-determining regions VL CDR1, VL CDR2, and VL CDR3, wherein... The VH CDR1 contains the amino acid sequence of SEQ ID NO:
3. The VH CDR2 contains the amino acid sequence of SEQ ID NO: 4 or 9. The VH CDR3 contains the amino acid sequence of SEQ ID NO:
5. The VL CDR1 contains the amino acid sequence of SEQ ID NO:
6. The VL CDR2 contains the amino acid sequence of SEQ ID NO: 7, and The VL CDR3 contains the amino acid sequence of SEQ ID NO:
8.
2. The antibody-drug conjugate according to claim 1, wherein the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 3, the VH CDR2 comprises the amino acid sequence of SEQ ID NO: 4, the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 5, the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 6, the VL CDR2 comprises the amino acid sequence of SEQ ID NO: 7, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO:
8.
3. The antibody-drug conjugate of claim 2, wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1 and 10 to 13, and the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 2 and 14 to 17.
4. The antibody-drug conjugate according to claim 2, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 11, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:
14.
5. The antibody-drug conjugate according to any one of claims 1 to 4, wherein the antibody-drug conjugate is humanized.
6. The antibody-drug conjugate according to any one of claims 1 to 5, wherein the antibody or its antigen-binding fragment further comprises a heavy chain constant region, a light chain constant region, an Fc region, or a combination thereof.
7. The antibody-drug conjugate according to any one of claims 1 to 6, wherein the antibody or its antigen-binding fragment is an isotype of IgG1, IgG2, IgG3 or IgG4.
8. The antibody-drug conjugate according to claim 7, wherein the antibody or its antigen-binding fragment is an isotype of human IgG1.
9. The antibody-drug conjugate according to any one of claims 1 to 8, wherein the drug portion is a cytotoxic agent or cell inhibitor, an immunosuppressant, a radioactive isotope, or a toxin.
10. The antibody-drug conjugate according to claim 9, wherein the drug portion is selected from the group consisting of: auristatin, maytansine alkaloids, macrocyclic ketone analogs, topoisomerase inhibitors, benzodiazepines, tubulolysin, pyroxine, camptothecin, chalcogenine, eczemaconazole, irinotecan (SN38), doxorubicin, anthracycline, pyrrolobenzodiazepines (PBD), TLR agonists, STING agonists, Pseudomonas aeruginosa exotoxin PE38, diphtheria toxin, Staphylococcus aureus enterotoxin A / E-120, antimicrobial antibiotics, shiga toxin, ricin, and urease.
11. The antibody-drug conjugate of claim 9, wherein the drug moiety is a cytotoxic agent selected from the group consisting of: monomethylaurestatin E (MMAE), monomethylaurestatin F (MMAF), maytansine, methylamycin (DM1), lavantenin (DM4), tubulolysin A, DXd, 7-ethyl-10-hydroxycamptothecin (SN-38), DGN462, amberstatin 269, atromycin, SG3199 / SCX, IRDye®700DX, TLR7 / 8 agonist, diABZI STING agonist-2, or any derivative thereof.
12. The antibody-drug conjugate according to any one of claims 9 to 11, wherein the drug portion comprises MMAE, MMAF, or DXd.
13. The antibody-drug conjugate of claim 9, wherein the drug portion comprises a compound selected from the group consisting of: (LM-D01) (LM-D02) and (LM-D03).
14. The antibody-drug conjugate according to any one of claims 1 to 13, wherein the antibody or its antigen-binding fragment is conjugated to the drug portion via a linker.
15. The antibody-drug conjugate of claim 14, wherein the connector is a cuttable connector or an uncuttable connector.
16. The antibody-drug conjugate of claim 15, wherein the adapter is a cuttable adapter.
17. The antibody-drug conjugate according to any one of claims 14 to 16, wherein the linker comprises succinimide-4-(N-maleimidemethyl)cyclohexane-1-carboxylic acid ester (SMCC), sulfonyl-SMCC, p-carboxycyclohexylmethylmaleimide, maleimide-hexanoyl (MC)-valine-citrulline (VC)-p-aminobenzyloxycarbamoyl (PABC), CL2A, maleimide-hexanoyl (MC), MC-glycine-glycine-phenylalanine-glycine (GGFG), MC-PEG8-GGFG, MC-PEG8-GGFG-PAB, or maleimide propionyl (MP)-PEG8-valine-alanine (VA)-PABC.
18. The antibody-drug conjugate according to any one of the preceding claims, wherein the antibody-drug conjugate comprises ozogamicin, vedotin, mafodotin, emtansine, deruxtecan, govitecan, or tesirine.
19. The antibody-drug conjugate according to any one of claims 1 to 18, wherein the drug-antibody ratio (DAR) is 1 to 20.
20. The antibody-drug conjugate according to any one of claims 1 to 18, wherein the drug-antibody ratio (DAR) is 4 to 8.
21. A composition comprising an antibody-drug conjugate according to any one of claims 1 to 20 and a pharmaceutically acceptable carrier.
22. A method of treating cancer in a patient in need, the method comprising administering to the patient an antibody-drug conjugate according to any one of claims 1 to 20 or a composition according to claim 21.
23. Use of the antibody-drug conjugate according to any one of claims 1 to 20 or the composition according to claim 21 in the preparation of a medicament for treating cancer.
24. The antibody-drug conjugate according to any one of claims 1 to 20 or the composition according to claim 21, for treating cancer in patients in need.
25. The antibody-drug conjugate or composition according to claim 22, the use according to claim 23, or the use according to claim 24, wherein the cancer is selected from the group consisting of: bladder cancer, liver cancer, colon cancer, rectal cancer, endometrial cancer, leukemia, lymphoma, pancreatic cancer, small cell lung cancer, non-small cell lung cancer, breast cancer, urethral cancer, head and neck cancer, gastrointestinal cancer, gastric cancer, esophageal cancer, ovarian cancer, kidney cancer, melanoma, prostate cancer, and thyroid cancer.
Citation Information
Patent Citations
Antibody-drug conjugate
US10195288B2
Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5773001A
Production of a single-gene-encoded immunoglobulin
US5892019A
Monomethylvaline compounds capable of conjugation to ligands
US7498298B2
